CFG920 is a non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 with potential antiandrogen and antineoplastic activities. In this Phase I/II study CFG920 will be administered orally in patients with metastatic castration-resistant prostate cancer after progressing (or have refused) on Abiraterone and Docetaxel.
Title: Phase III randomized study to compare the early chemotherapy with Docetaxel plus androgen ablation to androgen ablation alone in prostate cancer patients with extensive disease.
Metformin is widely used anti-diabetic medicine. It can also act as an anti-cancer agent by activation of AMP-activated protein kinase (AMPK) pathway and subsequent inhibition of mTOR that blocks the cancer cell growth and proliferation. It may also lessen the symptoms of metabolic syndrome caused by androgen deprivation therapy. In this Phase II study patients with advanced prostate cancer will be randomly selected to receive castration only or castration plus metformin as first line treatment.
For veterans only; Patients will take Nexrutine® (an oral dietary supplement) prior to and during radiation treatment for prostate cancer or prior to surgery for prostate cancer. The purpose of the study is to see whether taking Nexrutine® will cause the PSA (Prostate Specific Antigen) to decline.